Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Bio-Techne stock

Learn how to easily invest in Bio-Techne stock.

Bio-Techne is a biotechnology business based in the US. Bio-Techne shares (TECH) are listed on the NASDAQ and all prices are listed in US Dollars. Bio-Techne employs 3,000 staff and has a trailing 12-month revenue of around $1.1 billion.

How to buy Bio-Techne stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – TECH. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance



  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Bio-Techne stock price (NASDAQ: TECH)

Use our graph to track the performance of TECH stocks over time.

Bio-Techne shares at a glance

Information last updated 2023-01-26.
Latest market close$79.83
52-week range$67.68 - $113.06
50-day moving average $83.24
200-day moving average $85.74
Wall St. target price$104.89
PE ratio 44.5978
Dividend yield $0.32 (0.4%)
Earnings per share (TTM) $1.79

Buy Bio-Techne stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Bio-Techne stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bio-Techne price performance over time

Historical closes compared with the close of $79.83 from 2023-01-25

1 week (2023-01-20) -2.00%
1 month (2022-12-27) -2.90%
3 months (2022-10-27) -73.01%
6 months (2022-07-27) -78.68%
1 year (2022-01-27) -77.44%
2 years (2021-01-27) -74.93%
3 years (2020-01-27) 216.79
5 years (2018-01-26) 142.32

Is Bio-Techne stock undervalued or overvalued?

Valuing Bio-Techne stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bio-Techne's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bio-Techne's P/E ratio

Bio-Techne's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 45x. In other words, Bio-Techne shares trade at around 45x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Bio-Techne's PEG ratio

Bio-Techne's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1476. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bio-Techne's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Bio-Techne's EBITDA

Bio-Techne's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $358.5 million.

The EBITDA is a measure of a Bio-Techne's overall financial performance and is widely used to measure a its profitability.

Bio-Techne financials

Revenue TTM $1.1 billion
Operating margin TTM 26.5%
Gross profit TTM $758.1 million
Return on assets TTM 8.01%
Return on equity TTM 16.71%
Profit margin 26.13%
Book value $11.16
Market capitalisation $12.5 billion

TTM: trailing 12 months

Bio-Techne share dividends


Dividend payout ratio: 28.43% of net profits

Recently Bio-Techne has paid out, on average, around 28.43% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.4% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bio-Techne shareholders could enjoy a 0.4% return on their shares, in the form of dividend payments. In Bio-Techne's case, that would currently equate to about $0.32 per share.

While Bio-Techne's payout ratio might seem fairly standard, it's worth remembering that Bio-Techne may be investing much of the rest of its net profits in future growth.

Bio-Techne's most recent dividend payout was on 27 November 2022. The latest dividend was paid out to all shareholders who bought their shares by 9 November 2022 (the "ex-dividend date").

Have Bio-Techne's shares ever split?

Bio-Techne's shares were split on a 4:1 basis on 29 November 2022. So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Bio-Techne shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for Bio-Techne shares which in turn could have impacted Bio-Techne's share price.

Bio-Techne share price volatility

Over the last 12 months, Bio-Techne's shares have ranged in value from as little as $67.675 up to $113.0563. A popular way to gauge a stock's volatility is its "beta".

TECH.US volatility(beta: 1.25)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bio-Techne's is 1.2515. This would suggest that Bio-Techne's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Bio-Techne overview

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.

Frequently asked questions

What percentage of Bio-Techne is owned by insiders or institutions?
Currently 0.881% of Bio-Techne shares are held by insiders and 97.795% by institutions.
How many people work for Bio-Techne?
Latest data suggests 3,000 work at Bio-Techne.
When does the fiscal year end for Bio-Techne?
Bio-Techne's fiscal year ends in June.
Where is Bio-Techne based?
Bio-Techne's address is: 614 McKinley Place N.E., Minneapolis, MN, United States, 55413
What is Bio-Techne's ISIN number?
Bio-Techne's international securities identification number is: US09073M1045
What is Bio-Techne's CUSIP number?
Bio-Techne's Committee on Uniform Securities Identification Procedures number is: 878377100

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site